Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

The award-winning studies open new avenues for preventing arrhythmias caused by air pollution and for developing new therapeutic strategies against heart failure.

Researchers incorporate advanced cardiovascular prediction algorithms into cardiac imaging software, enabling the automatic calculation of the risk of serious complications during the routine analysis of cardiac studies.

Vall d’Hebron participates as a reference centre in Spain for early-phase clinical trials and coordinates the national ReALLNet network, promoting research into relapsed acute lymphoblastic leukemia.

The event focused on advances in disease-modifying therapies and on the value of alliances between patients and professionals to promote more participatory care and research.

The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The event brought together experts from the Vall d’Hebron Institute of Research (VHIR) and the Institute of Geosciences of Barcelona to analyze how environmental factors and the climate crisis impact population health.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

The accumulation of metabolic products within cardiac cells alters their function and accelerates the deterioration of heart tissue with age.

The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

A study led by the Vall d'Hebron Research Institute (VHIR) demonstrates the causal role of air pollution in ventricular arrhythmias and identifies a possible therapeutic strategy based on antioxidants.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.

The charitable initiative created in honor of Pol is supporting a research project aimed at identifying therapeutic targets to treat a rare type of leukemia.

The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The funds raised will contribute to ensuring the continuity of the pediatric brain tumor research line developed by the Vall d’Hebron research teams.

2025 has been an active year with the participation of RADeep members at the Data Access Committee at Vall d’Hebron and the presentation of abstracts at the 67th ASH Annual Meeting and Exposition.

Since 2019, Pulseras Candela has been collaborating with the Childhood Cancer and Hematological Diseases group at VHIR on the project “New Therapeutic Approaches for the Treatment of Pediatric Ependymoma.”

The session has helped bring the public an up-to-date perspective on diagnosis, treatments, and the research lines that are transforming the future of patients.